Division for Neurogeriatrics, Department of NVS, Center for Alzheimer Research, Karolinska Institutet, 141 57 Huddinge, Sweden.
Spiber Technologies AB, 106 91 Stockholm, Sweden.
Nat Commun. 2017 May 23;8:15504. doi: 10.1038/ncomms15504.
Membrane proteins are targets of most available pharmaceuticals, but they are difficult to produce recombinantly, like many other aggregation-prone proteins. Spiders can produce silk proteins at huge concentrations by sequestering their aggregation-prone regions in micellar structures, where the very soluble N-terminal domain (NT) forms the shell. We hypothesize that fusion to NT could similarly solubilize non-spidroin proteins, and design a charge-reversed mutant (NT*) that is pH insensitive, stabilized and hypersoluble compared to wild-type NT. NT*-transmembrane protein fusions yield up to eight times more of soluble protein in Escherichia coli than fusions with several conventional tags. NT* enables transmembrane peptide purification to homogeneity without chromatography and manufacture of low-cost synthetic lung surfactant that works in an animal model of respiratory disease. NT* also allows efficient expression and purification of non-transmembrane proteins, which are otherwise refractory to recombinant production, and offers a new tool for reluctant proteins in general.
膜蛋白是大多数现有药物的靶点,但它们像许多其他易聚集的蛋白质一样,难以通过重组方式产生。蜘蛛可以通过将其易聚集的区域隔离在胶束结构中来大量产生丝蛋白,其中非常可溶性的 N 端结构域(NT)形成外壳。我们假设融合到 NT 可以类似地使非丝蛋白溶解,并设计了一种电荷反转突变体(NT*),与野生型 NT 相比,它对 pH 不敏感、稳定且超溶。与几种传统标签相比,NT*-跨膜蛋白融合在大肠杆菌中产生的可溶性蛋白最多可增加八倍。NT可实现跨膜肽的纯净化,而无需色谱法,并可制造廉价的合成肺表面活性剂,在呼吸疾病的动物模型中有效。NT还允许易聚集的非跨膜蛋白的有效表达和纯化,否则这些蛋白难以通过重组生产,并且为一般情况下难以表达的蛋白提供了新的工具。